206 related articles for article (PubMed ID: 38330382)
21. Major clinical research advances in gynecologic cancer in 2012.
Suh DH; Kim JW; Kim K; Kim HJ; Lee KH
J Gynecol Oncol; 2013 Jan; 24(1):66-82. PubMed ID: 23346316
[TBL] [Abstract][Full Text] [Related]
22. Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancers.
Tolba MF; Elghazaly H; Bousoik E; Elmazar MMA; Tolaney SM
Clin Transl Oncol; 2021 Oct; 23(10):1979-1994. PubMed ID: 33871826
[TBL] [Abstract][Full Text] [Related]
23. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
Lau CH; Seow KM; Chen KH
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
[TBL] [Abstract][Full Text] [Related]
24. A review of recent advances on single use of antibody-drug conjugates or combination with tumor immunology therapy for gynecologic cancer.
Wang AJ; Gao Y; Shi YY; Dai MY; Cai HB
Front Pharmacol; 2022; 13():1093666. PubMed ID: 36618922
[TBL] [Abstract][Full Text] [Related]
25. Recent Therapeutic Advances in Gynecologic Oncology: A Review.
Wilson EM; Eskander RN; Binder PS
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398161
[TBL] [Abstract][Full Text] [Related]
26. Integrating antibody drug conjugates in the management of gynecologic cancers.
Chelariu-Raicu A; Mahner S; Moore KN; Lorusso D; Coleman RL
Int J Gynecol Cancer; 2023 Mar; 33(3):420-429. PubMed ID: 36878560
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy in Cervical Cancer.
Mauricio D; Zeybek B; Tymon-Rosario J; Harold J; Santin AD
Curr Oncol Rep; 2021 Apr; 23(6):61. PubMed ID: 33852056
[TBL] [Abstract][Full Text] [Related]
28. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
Campos MP; Konecny GE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
[TBL] [Abstract][Full Text] [Related]
29. Complete Response of a Mutated BRCA2 Metastatic Clear Cell Endometrial Adenocarcinoma to the Poly (ADP ribose) Polymerase (PARP) Inhibitor Olaparib.
Anzellini D; Arcangeli G; Del Bianco S
Cancer Diagn Progn; 2022; 2(1):84-86. PubMed ID: 35400012
[TBL] [Abstract][Full Text] [Related]
30. Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.
Guo Q; Yang Q; Li J; Liu G; Nikoulin I; Jia S
Curr Pharm Biotechnol; 2018; 19(14):1114-1121. PubMed ID: 30585545
[TBL] [Abstract][Full Text] [Related]
31. [Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates].
Dalenc F; Sarradin V; Nicolaï V; Franchet C; Ung M
Bull Cancer; 2021 Jan; 108(1):67-79. PubMed ID: 33422340
[TBL] [Abstract][Full Text] [Related]
32. Immuno-oncology for Gynecologic Malignancies.
How J; Patel A; Jazaeri A
Adv Exp Med Biol; 2020; 1244():149-182. PubMed ID: 32301014
[TBL] [Abstract][Full Text] [Related]
33. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
34. Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer.
Revythis A; Limbu A; Mikropoulos C; Ghose A; Sanchez E; Sheriff M; Boussios S
Int J Environ Res Public Health; 2022 Jul; 19(14):. PubMed ID: 35886427
[TBL] [Abstract][Full Text] [Related]
35. Immuno-Oncology for Gynecologic Malignancies.
How JA; Patel A; Jazaeri AA
Adv Exp Med Biol; 2021; 1342():193-232. PubMed ID: 34972966
[TBL] [Abstract][Full Text] [Related]
36. Major clinical research advances in gynecologic cancer in 2011.
Suh DH; Kim K; Kim JW
J Gynecol Oncol; 2012 Jan; 23(1):53-64. PubMed ID: 22355468
[TBL] [Abstract][Full Text] [Related]
37. Major clinical research advances in gynecologic cancer in 2014.
Suh DH; Lee KH; Kim K; Kang S; Kim JW
J Gynecol Oncol; 2015 Apr; 26(2):156-67. PubMed ID: 25872896
[TBL] [Abstract][Full Text] [Related]
38. Treating Prostate Cancer by Antibody-Drug Conjugates.
Rosellini M; Santoni M; Mollica V; Rizzo A; Cimadamore A; Scarpelli M; Storti N; Battelli N; Montironi R; Massari F
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33557050
[TBL] [Abstract][Full Text] [Related]
39. The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies.
Reinbolt RE; Hays JL
Front Oncol; 2013 Oct; 3():237. PubMed ID: 24098868
[TBL] [Abstract][Full Text] [Related]
40. Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?
Vergote I; Ray-Coquard I; Lorusso D; Oaknin A; Cibula D; Van Gorp T
Expert Opin Investig Drugs; 2023 Mar; 32(3):201-211. PubMed ID: 36803278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
